$ACB

Aurora Cannabis (ACB) refuted Curaleaf's (CURA) attempt to halt its ATM program, calling it a distraction from Curaleaf's undervalued hostile bid. Aurora highlighted Curaleaf's $1B debt and regulatory deficiencies, while emphasizing its own debt-free status and growth strategy. Aurora's board unanimously recommends shareholders reject Curaleaf's bid.

Curaleaf (CURLF) filed an application with the Alberta Securities Commission to halt Aurora's (ACB) at-the-market share issuance program, arguing it dilutes shareholders and increases the cost of Curaleaf's offer. Aurora has issued ~2.81M shares since Curaleaf's interest, diluting shareholders by ~4.9% and raising the offer cost by over US$11M. Curaleaf seeks an expedited hearing to protect Aurora shareholders.

Tilray (TLRY), Canopy Growth (CGC), and Aurora Cannabis (ACB) stocks rose on reports of potential U.S. marijuana reclassification. TLRY +14%, CGC +21%, ACB +7%. Analysts expect ACB to gain 46%, TLRY 28%, CGC 26% from current levels. Companies pursue different growth strategies globally.

Curaleaf Holdings (CURLF) defended its $4.00-$5.00 takeover bid for Aurora Cannabis, citing a 45% premium and better financial performance. Aurora rejected the offer, and Curaleaf urged a shorter bid period. The deal, if successful, would be transformative for Curaleaf but faces opposition and dilution risks.

Aurora Cannabis (ACB) reported fiscal 2027 Q1 revenue of C$67.6M, with international growth but declining profitability and negative free cash flow. The company focuses on global medical cannabis and plant propagation, aiming for higher margins. Investors watch for international sales expansion and cash flow recovery amid sector risks.

Aurora Cannabis (ACB) urged shareholders to reject Curaleaf's (CURA) hostile takeover bid, citing its debt-free status and $149M cash position. Aurora's CEO criticized the offer, claiming it undervalues assets and shifts risks. Curaleaf's CEO expressed willingness to discuss the merger, which was proposed at $4 per Aurora share.

Aurora Cannabis rejected Curaleaf's hostile bid, valuing it at $4 per share. Aurora's board seeks other strategic options, citing undervaluation and growth prospects. Curaleaf's offer included cash and stock, with a cap of $5 per share. Aurora highlights its debt-free status and cash reserves, while Curaleaf points to Aurora's recent share sales and dilution.

Aurora Cannabis CEO Miguel Martin rejected Curaleaf's $5 per share takeover bid, citing undervaluation of Aurora's EU-certified cannabis assets. Martin highlighted Aurora's debt-free status, cash reserves, and the strategic value of its EU GMP-certified facilities, which are crucial for accessing key medical cannabis markets. The board, supported by an independent committee, believes the offer undervalues the company and invites better offers.

Curaleaf (CURA, CURLF) defended its acquisition offer for Aurora Cannabis (ACB), citing a 45% premium and superior financials. Aurora's management has diluted shareholders through equity issuances and faces declining revenue and EBITDA, according to Curaleaf. Aurora's board sold shares below the offer price, contradicting its valuation argument.

Curaleaf Holdings defended its takeover bid for Aurora Cannabis, arguing its offer provides a 45% premium and long-term benefits. Aurora's board unanimously recommended shareholders reject the bid, citing undervaluation and risks. Curaleaf criticized Aurora's financial outlook and equity dilution, while Aurora maintained the offer undervalues the company. Curaleaf reported positive cash flow and growth investments for 2026.